RECRUITING

Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an individual will choose. The purpose of this study is to observe the changes an individual experiences in their relationship and reaction to food and in their food selection prior to or within the first two weeks of taking GLP-1 medication to after three months on the medication. The researchers of this study believe that an understanding of such changes can inform questions seeking to ensure maintenance of appropriate nutrient balance within individuals on weight loss medications.

Official Title

Exploring the Influence of GLP-1 Medication on Food Attitudes and Selection in a Virtual Reality Buffet

Quick Facts

Study Start:2025-07-15
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06843512

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults (18+) with overweight or obesity (BMI \>25 kg/m2)
  2. * Not currently taking an incretin-based medication at baseline
  3. * Recently (within two weeks) prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia)
  4. * Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
  5. * Fluent in English
  1. * Adults (18+) without overweight or obesity
  2. * \<18 years of age at time of testing
  3. * Adults not taking a GLP-1 Medication
  4. * Adults taking a compound GLP-1
  5. * Adults on GLP-1 medication for longer than 2 weeks at baseline
  6. * Have had a prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
  7. * Not fluent in English

Contacts and Locations

Study Contact

Christina M Blackmon
CONTACT
425-499-8049
cmb8633@psu.edu

Principal Investigator

Travis Masterson
PRINCIPAL_INVESTIGATOR
The Pennsylvania State University

Study Locations (Sites)

Health, Ingestive Behavior, and Technology Laboratory of Pennsylvania State University
State College, Pennsylvania, 16802
United States

Collaborators and Investigators

Sponsor: Penn State University

  • Travis Masterson, PRINCIPAL_INVESTIGATOR, The Pennsylvania State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-15
Study Completion Date2026-12

Study Record Updates

Study Start Date2025-07-15
Study Completion Date2026-12

Terms related to this study

Keywords Provided by Researchers

  • GLP-1
  • Weight Loss
  • Virtual Reality
  • Food behavior

Additional Relevant MeSH Terms

  • Weight Loss
  • Food Selection